HPV subtypes and immunological parameters of cervical cancer in Iceland during two time periods, 1958–1960 and 1995–1996

Cervical cancer is a disease caused in part by an infection with an oncogenic subtype of human papillomavirus (HPV). In this study we analysed all cervical cancer samples diagnosed in Iceland during two periods, 1958–1960 and 1995–1996, and asked whether significant changes in viral or immunological...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gynecologic oncology 2003-04, Vol.89 (1), p.22-30
Hauptverfasser: Mikaelsdottir, Evgenia K, Benediktsdottir, Kristrun R, Olafsdottir, Kristrun, Arnadottir, Thorgerdur, Ragnarsson, Gunnar B, Olafsson, Karl, Sigurdsson, Kristjan, Kristjansdottir, Gudny S, Imsland, Albert K, Ögmundsdottir, Helga M, Rafnar, Thorunn
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 30
container_issue 1
container_start_page 22
container_title Gynecologic oncology
container_volume 89
creator Mikaelsdottir, Evgenia K
Benediktsdottir, Kristrun R
Olafsdottir, Kristrun
Arnadottir, Thorgerdur
Ragnarsson, Gunnar B
Olafsson, Karl
Sigurdsson, Kristjan
Kristjansdottir, Gudny S
Imsland, Albert K
Ögmundsdottir, Helga M
Rafnar, Thorunn
description Cervical cancer is a disease caused in part by an infection with an oncogenic subtype of human papillomavirus (HPV). In this study we analysed all cervical cancer samples diagnosed in Iceland during two periods, 1958–1960 and 1995–1996, and asked whether significant changes in viral or immunological parameters had occurred over a period that spanned both significant changes in sexual attitude and the implementation of organized screening for cervical cancer. Samples from 47 patients (46 squamous cell carcinomas (SCC) and 1 adenosquamous carcinoma (ASC)) in the first period and 30 patients (20 SCC, 4 ASC, and 6 adenocarcinomas (AC)) in the later period were analysed for viral subtype and expression of Fas, FasL, MHC class I, p53 and apoptosis. AC and ASC are proportionately much more common today than 40 years ago (30% vs 2%). The distribution of HPV in cervical cancer is similar in both periods, with HPV16 found in 75% and HPV18 in 13% of cases. Other HPV types found were 31,33,45, and 59. No significant differences were found in the immunological profiles of tumors from the two periods except that a higher fraction of SCC in the later period stained positive for FasL. When SCC are compared with AC/ASC, the latter have less expression of MHC class I, less expression of Fas, and stronger FasL expression. AC/ASC tumors show some immunological features that suggest that they are more resistant to immune attack than SCC.
doi_str_mv 10.1016/S0090-8258(03)00053-2
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73178847</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090825803000532</els_id><sourcerecordid>73178847</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-d8ac1fd16d05ef0d366378ef76d5caa191f7329d284bc31be08160d4169468a23</originalsourceid><addsrcrecordid>eNqFkN9qFTEQh4Mo9rT6CEpuFAVXZzabbHJVpFRbKCj45zbkJNkSObtZk91KwQvfwTf0SczuOdhLr5IM38z88hHyBOE1Aoo3nwAUVLLm8gWwlwDAWVXfIxsExSshubpPNv-QI3Kc87cCMcD6ITnCWqhGcNiQnxcfv9I8b6fb0WdqBkdD389D3MXrYM2OjiaZ3k8-ZRo7an26WcvWDOVOw0Avrd8tbW5OYbim049Ip9B7OvoUosuvKCou__z6jUrAOh-V4utbiUfkQWd22T8-nCfky7vzz2cX1dWH95dnb68qyxROlZPGYudQOOC-A8eEYK30XSsct8agwq5ltXK1bLaW4daDRAGuweWT0tTshDzfzx1T_D77POk-5JK7BPdxzrpl2ErZtAXke9CmmHPynR5T6E261Qh60a5X7XpxqoHpVbteFjw9LJi3vXd3XQfPBXh2AEwu_rpU_IV8xzUtKCFZ4U73nC86boJPOtvgi2sXkreTdjH8J8pfjRmefg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73178847</pqid></control><display><type>article</type><title>HPV subtypes and immunological parameters of cervical cancer in Iceland during two time periods, 1958–1960 and 1995–1996</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Mikaelsdottir, Evgenia K ; Benediktsdottir, Kristrun R ; Olafsdottir, Kristrun ; Arnadottir, Thorgerdur ; Ragnarsson, Gunnar B ; Olafsson, Karl ; Sigurdsson, Kristjan ; Kristjansdottir, Gudny S ; Imsland, Albert K ; Ögmundsdottir, Helga M ; Rafnar, Thorunn</creator><creatorcontrib>Mikaelsdottir, Evgenia K ; Benediktsdottir, Kristrun R ; Olafsdottir, Kristrun ; Arnadottir, Thorgerdur ; Ragnarsson, Gunnar B ; Olafsson, Karl ; Sigurdsson, Kristjan ; Kristjansdottir, Gudny S ; Imsland, Albert K ; Ögmundsdottir, Helga M ; Rafnar, Thorunn</creatorcontrib><description>Cervical cancer is a disease caused in part by an infection with an oncogenic subtype of human papillomavirus (HPV). In this study we analysed all cervical cancer samples diagnosed in Iceland during two periods, 1958–1960 and 1995–1996, and asked whether significant changes in viral or immunological parameters had occurred over a period that spanned both significant changes in sexual attitude and the implementation of organized screening for cervical cancer. Samples from 47 patients (46 squamous cell carcinomas (SCC) and 1 adenosquamous carcinoma (ASC)) in the first period and 30 patients (20 SCC, 4 ASC, and 6 adenocarcinomas (AC)) in the later period were analysed for viral subtype and expression of Fas, FasL, MHC class I, p53 and apoptosis. AC and ASC are proportionately much more common today than 40 years ago (30% vs 2%). The distribution of HPV in cervical cancer is similar in both periods, with HPV16 found in 75% and HPV18 in 13% of cases. Other HPV types found were 31,33,45, and 59. No significant differences were found in the immunological profiles of tumors from the two periods except that a higher fraction of SCC in the later period stained positive for FasL. When SCC are compared with AC/ASC, the latter have less expression of MHC class I, less expression of Fas, and stronger FasL expression. AC/ASC tumors show some immunological features that suggest that they are more resistant to immune attack than SCC.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1016/S0090-8258(03)00053-2</identifier><identifier>PMID: 12694650</identifier><identifier>CODEN: GYNOA3</identifier><language>eng</language><publisher>San Diego, CA: Elsevier Inc</publisher><subject>Adenocarcinoma - immunology ; Adenocarcinoma - pathology ; Adenocarcinoma - virology ; Apoptosis ; Apoptosis - immunology ; Biological and medical sciences ; Carcinoma, Adenosquamous - immunology ; Carcinoma, Adenosquamous - pathology ; Carcinoma, Adenosquamous - virology ; Carcinoma, Squamous Cell - immunology ; Carcinoma, Squamous Cell - pathology ; Carcinoma, Squamous Cell - virology ; Cervical cancer ; DNA, Viral - genetics ; Fas ; Fas ligand ; Fas Ligand Protein ; fas Receptor - biosynthesis ; Female ; Female genital diseases ; Gynecology. Andrology. Obstetrics ; Histocompatibility Antigens Class I - biosynthesis ; HLA class I ; HPV ; Humans ; Iceland ; Immunohistochemistry ; Medical sciences ; Membrane Glycoproteins - biosynthesis ; p53 ; Papillomaviridae - classification ; Papillomaviridae - genetics ; Papillomavirus Infections - complications ; Papillomavirus Infections - virology ; Tumor Suppressor Protein p53 - biosynthesis ; Tumor Virus Infections - complications ; Tumor Virus Infections - virology ; Tumors ; Uterine Cervical Neoplasms - immunology ; Uterine Cervical Neoplasms - pathology ; Uterine Cervical Neoplasms - virology</subject><ispartof>Gynecologic oncology, 2003-04, Vol.89 (1), p.22-30</ispartof><rights>2003 Elsevier Science (USA)</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-d8ac1fd16d05ef0d366378ef76d5caa191f7329d284bc31be08160d4169468a23</citedby><cites>FETCH-LOGICAL-c391t-d8ac1fd16d05ef0d366378ef76d5caa191f7329d284bc31be08160d4169468a23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0090-8258(03)00053-2$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14709683$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12694650$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mikaelsdottir, Evgenia K</creatorcontrib><creatorcontrib>Benediktsdottir, Kristrun R</creatorcontrib><creatorcontrib>Olafsdottir, Kristrun</creatorcontrib><creatorcontrib>Arnadottir, Thorgerdur</creatorcontrib><creatorcontrib>Ragnarsson, Gunnar B</creatorcontrib><creatorcontrib>Olafsson, Karl</creatorcontrib><creatorcontrib>Sigurdsson, Kristjan</creatorcontrib><creatorcontrib>Kristjansdottir, Gudny S</creatorcontrib><creatorcontrib>Imsland, Albert K</creatorcontrib><creatorcontrib>Ögmundsdottir, Helga M</creatorcontrib><creatorcontrib>Rafnar, Thorunn</creatorcontrib><title>HPV subtypes and immunological parameters of cervical cancer in Iceland during two time periods, 1958–1960 and 1995–1996</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>Cervical cancer is a disease caused in part by an infection with an oncogenic subtype of human papillomavirus (HPV). In this study we analysed all cervical cancer samples diagnosed in Iceland during two periods, 1958–1960 and 1995–1996, and asked whether significant changes in viral or immunological parameters had occurred over a period that spanned both significant changes in sexual attitude and the implementation of organized screening for cervical cancer. Samples from 47 patients (46 squamous cell carcinomas (SCC) and 1 adenosquamous carcinoma (ASC)) in the first period and 30 patients (20 SCC, 4 ASC, and 6 adenocarcinomas (AC)) in the later period were analysed for viral subtype and expression of Fas, FasL, MHC class I, p53 and apoptosis. AC and ASC are proportionately much more common today than 40 years ago (30% vs 2%). The distribution of HPV in cervical cancer is similar in both periods, with HPV16 found in 75% and HPV18 in 13% of cases. Other HPV types found were 31,33,45, and 59. No significant differences were found in the immunological profiles of tumors from the two periods except that a higher fraction of SCC in the later period stained positive for FasL. When SCC are compared with AC/ASC, the latter have less expression of MHC class I, less expression of Fas, and stronger FasL expression. AC/ASC tumors show some immunological features that suggest that they are more resistant to immune attack than SCC.</description><subject>Adenocarcinoma - immunology</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma - virology</subject><subject>Apoptosis</subject><subject>Apoptosis - immunology</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Adenosquamous - immunology</subject><subject>Carcinoma, Adenosquamous - pathology</subject><subject>Carcinoma, Adenosquamous - virology</subject><subject>Carcinoma, Squamous Cell - immunology</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Carcinoma, Squamous Cell - virology</subject><subject>Cervical cancer</subject><subject>DNA, Viral - genetics</subject><subject>Fas</subject><subject>Fas ligand</subject><subject>Fas Ligand Protein</subject><subject>fas Receptor - biosynthesis</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Histocompatibility Antigens Class I - biosynthesis</subject><subject>HLA class I</subject><subject>HPV</subject><subject>Humans</subject><subject>Iceland</subject><subject>Immunohistochemistry</subject><subject>Medical sciences</subject><subject>Membrane Glycoproteins - biosynthesis</subject><subject>p53</subject><subject>Papillomaviridae - classification</subject><subject>Papillomaviridae - genetics</subject><subject>Papillomavirus Infections - complications</subject><subject>Papillomavirus Infections - virology</subject><subject>Tumor Suppressor Protein p53 - biosynthesis</subject><subject>Tumor Virus Infections - complications</subject><subject>Tumor Virus Infections - virology</subject><subject>Tumors</subject><subject>Uterine Cervical Neoplasms - immunology</subject><subject>Uterine Cervical Neoplasms - pathology</subject><subject>Uterine Cervical Neoplasms - virology</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkN9qFTEQh4Mo9rT6CEpuFAVXZzabbHJVpFRbKCj45zbkJNkSObtZk91KwQvfwTf0SczuOdhLr5IM38z88hHyBOE1Aoo3nwAUVLLm8gWwlwDAWVXfIxsExSshubpPNv-QI3Kc87cCMcD6ITnCWqhGcNiQnxcfv9I8b6fb0WdqBkdD389D3MXrYM2OjiaZ3k8-ZRo7an26WcvWDOVOw0Avrd8tbW5OYbim049Ip9B7OvoUosuvKCou__z6jUrAOh-V4utbiUfkQWd22T8-nCfky7vzz2cX1dWH95dnb68qyxROlZPGYudQOOC-A8eEYK30XSsct8agwq5ltXK1bLaW4daDRAGuweWT0tTshDzfzx1T_D77POk-5JK7BPdxzrpl2ErZtAXke9CmmHPynR5T6E261Qh60a5X7XpxqoHpVbteFjw9LJi3vXd3XQfPBXh2AEwu_rpU_IV8xzUtKCFZ4U73nC86boJPOtvgi2sXkreTdjH8J8pfjRmefg</recordid><startdate>20030401</startdate><enddate>20030401</enddate><creator>Mikaelsdottir, Evgenia K</creator><creator>Benediktsdottir, Kristrun R</creator><creator>Olafsdottir, Kristrun</creator><creator>Arnadottir, Thorgerdur</creator><creator>Ragnarsson, Gunnar B</creator><creator>Olafsson, Karl</creator><creator>Sigurdsson, Kristjan</creator><creator>Kristjansdottir, Gudny S</creator><creator>Imsland, Albert K</creator><creator>Ögmundsdottir, Helga M</creator><creator>Rafnar, Thorunn</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030401</creationdate><title>HPV subtypes and immunological parameters of cervical cancer in Iceland during two time periods, 1958–1960 and 1995–1996</title><author>Mikaelsdottir, Evgenia K ; Benediktsdottir, Kristrun R ; Olafsdottir, Kristrun ; Arnadottir, Thorgerdur ; Ragnarsson, Gunnar B ; Olafsson, Karl ; Sigurdsson, Kristjan ; Kristjansdottir, Gudny S ; Imsland, Albert K ; Ögmundsdottir, Helga M ; Rafnar, Thorunn</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-d8ac1fd16d05ef0d366378ef76d5caa191f7329d284bc31be08160d4169468a23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adenocarcinoma - immunology</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma - virology</topic><topic>Apoptosis</topic><topic>Apoptosis - immunology</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Adenosquamous - immunology</topic><topic>Carcinoma, Adenosquamous - pathology</topic><topic>Carcinoma, Adenosquamous - virology</topic><topic>Carcinoma, Squamous Cell - immunology</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Carcinoma, Squamous Cell - virology</topic><topic>Cervical cancer</topic><topic>DNA, Viral - genetics</topic><topic>Fas</topic><topic>Fas ligand</topic><topic>Fas Ligand Protein</topic><topic>fas Receptor - biosynthesis</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Histocompatibility Antigens Class I - biosynthesis</topic><topic>HLA class I</topic><topic>HPV</topic><topic>Humans</topic><topic>Iceland</topic><topic>Immunohistochemistry</topic><topic>Medical sciences</topic><topic>Membrane Glycoproteins - biosynthesis</topic><topic>p53</topic><topic>Papillomaviridae - classification</topic><topic>Papillomaviridae - genetics</topic><topic>Papillomavirus Infections - complications</topic><topic>Papillomavirus Infections - virology</topic><topic>Tumor Suppressor Protein p53 - biosynthesis</topic><topic>Tumor Virus Infections - complications</topic><topic>Tumor Virus Infections - virology</topic><topic>Tumors</topic><topic>Uterine Cervical Neoplasms - immunology</topic><topic>Uterine Cervical Neoplasms - pathology</topic><topic>Uterine Cervical Neoplasms - virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mikaelsdottir, Evgenia K</creatorcontrib><creatorcontrib>Benediktsdottir, Kristrun R</creatorcontrib><creatorcontrib>Olafsdottir, Kristrun</creatorcontrib><creatorcontrib>Arnadottir, Thorgerdur</creatorcontrib><creatorcontrib>Ragnarsson, Gunnar B</creatorcontrib><creatorcontrib>Olafsson, Karl</creatorcontrib><creatorcontrib>Sigurdsson, Kristjan</creatorcontrib><creatorcontrib>Kristjansdottir, Gudny S</creatorcontrib><creatorcontrib>Imsland, Albert K</creatorcontrib><creatorcontrib>Ögmundsdottir, Helga M</creatorcontrib><creatorcontrib>Rafnar, Thorunn</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mikaelsdottir, Evgenia K</au><au>Benediktsdottir, Kristrun R</au><au>Olafsdottir, Kristrun</au><au>Arnadottir, Thorgerdur</au><au>Ragnarsson, Gunnar B</au><au>Olafsson, Karl</au><au>Sigurdsson, Kristjan</au><au>Kristjansdottir, Gudny S</au><au>Imsland, Albert K</au><au>Ögmundsdottir, Helga M</au><au>Rafnar, Thorunn</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HPV subtypes and immunological parameters of cervical cancer in Iceland during two time periods, 1958–1960 and 1995–1996</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>2003-04-01</date><risdate>2003</risdate><volume>89</volume><issue>1</issue><spage>22</spage><epage>30</epage><pages>22-30</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><coden>GYNOA3</coden><abstract>Cervical cancer is a disease caused in part by an infection with an oncogenic subtype of human papillomavirus (HPV). In this study we analysed all cervical cancer samples diagnosed in Iceland during two periods, 1958–1960 and 1995–1996, and asked whether significant changes in viral or immunological parameters had occurred over a period that spanned both significant changes in sexual attitude and the implementation of organized screening for cervical cancer. Samples from 47 patients (46 squamous cell carcinomas (SCC) and 1 adenosquamous carcinoma (ASC)) in the first period and 30 patients (20 SCC, 4 ASC, and 6 adenocarcinomas (AC)) in the later period were analysed for viral subtype and expression of Fas, FasL, MHC class I, p53 and apoptosis. AC and ASC are proportionately much more common today than 40 years ago (30% vs 2%). The distribution of HPV in cervical cancer is similar in both periods, with HPV16 found in 75% and HPV18 in 13% of cases. Other HPV types found were 31,33,45, and 59. No significant differences were found in the immunological profiles of tumors from the two periods except that a higher fraction of SCC in the later period stained positive for FasL. When SCC are compared with AC/ASC, the latter have less expression of MHC class I, less expression of Fas, and stronger FasL expression. AC/ASC tumors show some immunological features that suggest that they are more resistant to immune attack than SCC.</abstract><cop>San Diego, CA</cop><pub>Elsevier Inc</pub><pmid>12694650</pmid><doi>10.1016/S0090-8258(03)00053-2</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0090-8258
ispartof Gynecologic oncology, 2003-04, Vol.89 (1), p.22-30
issn 0090-8258
1095-6859
language eng
recordid cdi_proquest_miscellaneous_73178847
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Adenocarcinoma - immunology
Adenocarcinoma - pathology
Adenocarcinoma - virology
Apoptosis
Apoptosis - immunology
Biological and medical sciences
Carcinoma, Adenosquamous - immunology
Carcinoma, Adenosquamous - pathology
Carcinoma, Adenosquamous - virology
Carcinoma, Squamous Cell - immunology
Carcinoma, Squamous Cell - pathology
Carcinoma, Squamous Cell - virology
Cervical cancer
DNA, Viral - genetics
Fas
Fas ligand
Fas Ligand Protein
fas Receptor - biosynthesis
Female
Female genital diseases
Gynecology. Andrology. Obstetrics
Histocompatibility Antigens Class I - biosynthesis
HLA class I
HPV
Humans
Iceland
Immunohistochemistry
Medical sciences
Membrane Glycoproteins - biosynthesis
p53
Papillomaviridae - classification
Papillomaviridae - genetics
Papillomavirus Infections - complications
Papillomavirus Infections - virology
Tumor Suppressor Protein p53 - biosynthesis
Tumor Virus Infections - complications
Tumor Virus Infections - virology
Tumors
Uterine Cervical Neoplasms - immunology
Uterine Cervical Neoplasms - pathology
Uterine Cervical Neoplasms - virology
title HPV subtypes and immunological parameters of cervical cancer in Iceland during two time periods, 1958–1960 and 1995–1996
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T23%3A28%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HPV%20subtypes%20and%20immunological%20parameters%20of%20cervical%20cancer%20in%20Iceland%20during%20two%20time%20periods,%201958%E2%80%931960%20and%201995%E2%80%931996&rft.jtitle=Gynecologic%20oncology&rft.au=Mikaelsdottir,%20Evgenia%20K&rft.date=2003-04-01&rft.volume=89&rft.issue=1&rft.spage=22&rft.epage=30&rft.pages=22-30&rft.issn=0090-8258&rft.eissn=1095-6859&rft.coden=GYNOA3&rft_id=info:doi/10.1016/S0090-8258(03)00053-2&rft_dat=%3Cproquest_cross%3E73178847%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73178847&rft_id=info:pmid/12694650&rft_els_id=S0090825803000532&rfr_iscdi=true